Please login to the form below
Sarepta
This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.
Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy
LGMD). Søren Tulstrup, president and chief executive officer of Hansa, said: "We are very excited about the results we have seen in the preclinical phase of our collaboration with Sarepta. ... Sarepta submitted a Biologics License Application to the US
Latest news
-
Sarepta to submit application for Duchenne muscular dystrophy gene therapy
Sarepta Therapeutics has announced its intent to submit a Biologics License Application (BLA) to accelerate approval for SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant patients with Duchenne muscular dystrophy ... Doug Ingram,
-
Sarepta Therapeutics’ DMD gene therapy shows early success
Sarepta Therapeutics has revealed some early promising data for its Duchenne muscular dystrophy (DMD), although the company also reported serious adverse events associated with the treatment. ... Although Sarepta did not identify any new safety signals
-
Lilly links up with Precision BioSciences in genome editing deal
Sarepta is also prominent in the DMD therapy area and the company's second approved DMD therapy Vyondys 53 (golodirsen) received approval last December. ... Vyondys 53 is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen).
-
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
The Roche deal is Dyno’s third pharma collaboration, in addition to its existing partnerships with Novartis and Sarepta Therapeutics. ... disease. The Sarepta deal is focused on the development of new AAV vectors for gene therapies aimed at targeting
-
FDA approves Sarepta rival NS Pharma’s Duchenne drug
The approval will see Viltepso enter a competitive market and likely head into a rivalry with Sarepta’s Vyondys 53 (golodirsen), which gained FDA approval last December.. ... Like NS Pharma, Sarepta is conducting a confirmatory trial of Vyondys 53
More from news
Approximately 21 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
-
Bluebird Bio: on the cusp of a gene therapy revolution
A gene therapy, and Duchenne pioneer Sarepta.
-
Deal Watch February 2017
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
-
Deal Watch October 2016
The licence deal obtained by Summit from Sarepta for a phase II product had an even lower upfront, 7% of the total consideration. ... 767. Sarepta (US). Summit (UK). Licence collaboration. Europe Utrophin modulator pipeline, lead molecule phase II for
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
-
Minoryx Therapeutics adds to board of directors
He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at Sarepta Therapeutics.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- Eli Lilly announces $450m investment in US manufacturing site
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Alzheimer’s Society urges UK government to deliver on dementia plan
- GSK fires senior Chinese scientist over data fabrication
- NICE set to recommend seven biologics for severe rheumatoid arthritis
- World Cancer Day: encouraging men to put their health first
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
